Coherus Oncology (NASDAQ:CHRS) used its presentation at the Citizens Life Sciences Conference to outline its transition into what CEO Denny Lanfear described as an “innovative oncology company focused ...

If you are wondering whether Merck's current share price still offers value, this article will walk through what the numbers are really saying about the stock. Merck closed at US$115.61, with returns ...